Non-melanoma skin cancer risk with Janus kinase inhibitors compared to interleukin-6 receptor inhibitors in rheumatoid arthritis: results from a national cohort study - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Risk of Non-Melanoma Skin Cancer Associated with Janus Kinase Inhibitors Versus Interleukin-6 Receptor Inhibitors in Rheumatoid Arthritis: Findings from a National Cohort Analysis

  • By

  • Zixing Tian

  • Lianne Kearsley-Fleet

  • Sizheng Steven Zhao

  • James Galloway

  • Mark Lunt

  • Kath Watson

  • Narges Azadbakht

  • Kimme L Hyrich

  • July 9, 2026

Share

Original Source(s)

Related Content